FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381337400> ?p ?o ?g. }

• W4381337400 abstract "Background: Statin use in adults with diabetes is sub-optimal. Coronary artery calcium (CAC) scoring can provide a visual quantification of CV risk and may improve statin initiation and long-term use. Objective: Estimate the cost-utility of CAC scoring compared to traditional CV risk counselling only, for improving statin use in adults with diabetes who have not previously had a CV event, and are not on statin therapy. Methods: Probabilistic Markov model from a health system perspective, over a 10-year time horizon. The effectiveness of CAC scoring was obtained from the EISNER trial. Outcomes included acute coronary syndrome (ACS), stroke, heart failure, mortality, and radiation-induced cancer. Outcome rates and costs were obtained from an analysis of Alberta administrative data, and from publicly available sources. The base population modeled was men age 60, with additional analyses for other age, sex-groups and scenarios. Results: CAC scoring increased statin use to 44% vs 25% with traditional CV risk counselling only. There were 8.4 fewer ACS, 5.5 fewer strokes, and 1.6 fewer deaths / 1000 individuals. Costs were slightly lower (-$14, 95% CI [-$402-(+$208)]) (CAD), for a small benefit in quality-adjusted life years (+0.01, [0.00-0.02]), with mean ICER of $7,132 (-$27,828-(+$65,513)) / QALY. At a willingness-to-pay of $50,000 / QALY, CAC was cost-effective in 95% of trials. CAC scoring was not cost-effective in younger men or in women, but could be cost-effective or cost savings in men (age ≥ 40) and older women (age ≥ 60) who refuse statin therapy, but would be persuaded by personalized evidence of coronary artery disease (CAC score &gt; 10). Conclusion: CAC scoring may be cost-effective in older men not receiving statins, and in men or older women who agree to use statins if shown personalized evidence of coronary artery disease. Disclosure D.Lau: None. G.J.Pearson: Advisory Panel; HLS Therapeutics Inc., Novartis Pharmaceuticals Corporation, Pharmacience, Consultant; Trimedic Therapeutics. P.Raggi: None. S.Klarenbach: Research Support; Bayer Inc., Allergan, GlaxoSmithKline plc., CSL Behring, Lundbeck, University Hospital Foundation (University of Alberta), Purdue Canada." @default.
• W4381337400 created "2023-06-21" @default.
• W4381337400 creator A5013497045 @default.
• W4381337400 creator A5016072225 @default.
• W4381337400 creator A5033662895 @default.
• W4381337400 creator A5061444639 @default.
• W4381337400 date "2023-06-20" @default.
• W4381337400 modified "2023-09-24" @default.
• W4381337400 title "992-P: Coronary Artery Calcium Scoring to Improve Statin Use in Adults with Type 2 Diabetes Not on Statin Therapy—Anticipated Cost Utility" @default.
• W4381337400 doi "https://doi.org/10.2337/db23-992-p" @default.
• W4381337400 hasPublicationYear "2023" @default.
• W4381337400 type Work @default.
• W4381337400 citedByCount "0" @default.
• W4381337400 crossrefType "journal-article" @default.
• W4381337400 hasAuthorship W4381337400A5013497045 @default.
• W4381337400 hasAuthorship W4381337400A5016072225 @default.
• W4381337400 hasAuthorship W4381337400A5033662895 @default.
• W4381337400 hasAuthorship W4381337400A5061444639 @default.
• W4381337400 hasConcept C112930515 @default.
• W4381337400 hasConcept C126322002 @default.
• W4381337400 hasConcept C127413603 @default.
• W4381337400 hasConcept C134018914 @default.
• W4381337400 hasConcept C184834754 @default.
• W4381337400 hasConcept C1862650 @default.
• W4381337400 hasConcept C2776839432 @default.
• W4381337400 hasConcept C2778213512 @default.
• W4381337400 hasConcept C2780645631 @default.
• W4381337400 hasConcept C2908647359 @default.
• W4381337400 hasConcept C3019080777 @default.
• W4381337400 hasConcept C555293320 @default.
• W4381337400 hasConcept C64332521 @default.
• W4381337400 hasConcept C71924100 @default.
• W4381337400 hasConcept C78519656 @default.
• W4381337400 hasConcept C99454951 @default.
• W4381337400 hasConceptScore W4381337400C112930515 @default.
• W4381337400 hasConceptScore W4381337400C126322002 @default.
• W4381337400 hasConceptScore W4381337400C127413603 @default.
• W4381337400 hasConceptScore W4381337400C134018914 @default.
• W4381337400 hasConceptScore W4381337400C184834754 @default.
• W4381337400 hasConceptScore W4381337400C1862650 @default.
• W4381337400 hasConceptScore W4381337400C2776839432 @default.
• W4381337400 hasConceptScore W4381337400C2778213512 @default.
• W4381337400 hasConceptScore W4381337400C2780645631 @default.
• W4381337400 hasConceptScore W4381337400C2908647359 @default.
• W4381337400 hasConceptScore W4381337400C3019080777 @default.
• W4381337400 hasConceptScore W4381337400C555293320 @default.
• W4381337400 hasConceptScore W4381337400C64332521 @default.
• W4381337400 hasConceptScore W4381337400C71924100 @default.
• W4381337400 hasConceptScore W4381337400C78519656 @default.
• W4381337400 hasConceptScore W4381337400C99454951 @default.
• W4381337400 hasIssue "Supplement_1" @default.
• W4381337400 hasLocation W43813374001 @default.
• W4381337400 hasOpenAccess W4381337400 @default.
• W4381337400 hasPrimaryLocation W43813374001 @default.
• W4381337400 hasRelatedWork W2016681914 @default.
• W4381337400 hasRelatedWork W2024201357 @default.
• W4381337400 hasRelatedWork W2041145027 @default.
• W4381337400 hasRelatedWork W2044064409 @default.
• W4381337400 hasRelatedWork W2069915399 @default.
• W4381337400 hasRelatedWork W2165676838 @default.
• W4381337400 hasRelatedWork W2310170993 @default.
• W4381337400 hasRelatedWork W2806736126 @default.
• W4381337400 hasRelatedWork W3119655573 @default.
• W4381337400 hasRelatedWork W2955835879 @default.
• W4381337400 hasVolume "72" @default.
• W4381337400 isParatext "false" @default.
• W4381337400 isRetracted "false" @default.
• W4381337400 workType "article" @default.